| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest Diagnostics, the world's leading provider of diagnostic information services, launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States. The new STD test packages are the first to be offered directly by Quest Diagnostics or any other major national laboratory to allow individuals to purchase tests at their discretion. These new packages have been designed to meet the needs of individuals who want accurate basic or comprehensive STD testing.[CR-LF][CR-LF]The new services are designed to empower individuals to access STD screening when they are reluctant to engage their healthcare provider directly. Research by Quest Diagnostics shows that patients and healthcare providers often fail to discuss sexual behavior and STD risk. According to a survey commissioned by Quest, 51 percent of females age 18-24 years say they don't want to bring up for discussion the topics of sex or STDs with their clinicians and 49 percent claim their clinician has never asked if they want STD testing.
Shares of Quest Diagnostics (DGX - Get Report) climbed 7.4% to $91.50 Tuesday after the diagnostic testing company reported better-than-expected first-quarter earnings.[CR-LF][CR-LF]The Secaucus, N.J.-based company reported net income of $164 million, or $1.20 a share, down from $177 million, or $1.52 a share, a year ago. Adjusted earnings came to $1.40 a share, surpassing analyst's forecasts of $1.36.[CR-LF][CR-LF]Revenue totaled $1.89 billion, up 0.4% from a year ago, and beat Wall Street's expectation of $1.87 billion. Cash provided by operations was $275 million, up 53.4% from 2018.
Quest Diagnostics (DGX) Q1 results: Revenues: $1,891M (+0.4%).[CR-LF][CR-LF]Net Income: $164M (-7.3%); Non-GAAP Net Income: $190M (-10.0%); EPS: $1.20 (-5.5%); Non-GAAP EPS: $1.40 (-7.9%); CF Ops: $275M (+52.8%).[CR-LF][CR-LF]2019 Guidance: Revenues: $7.6B - $7.75B (unch); EPS: >$5.16 (unch); Non-GAAP EPS: >$6.40 (unch); CF Ops: ~$1.3B (unch).[CR-LF][CR-LF]The consensus Revenue and GAAP EPS estimate was $1.87B and $1.38, respectively.
Quest Diagnostics (NYSE:DGX): Q1 Non-GAAP EPS of $1.40 beats by $0.02; GAAP EPS of $1.20. Revenue of $1.89B (+0.5% Y/Y) beats by $20M.
Tuesday morning's results are the first Quest has shared since getting back into the UnitedHealth network at the start of the year. The agreement with UnitedHealth has given Quest access to more patient lives than at any time in the past decade. Accordingly, organic requisition volume growth was up 2.4%, compared to 1.1% in the fourth quarter of 2018, and would have been around 3% if headwinds including a slightly shorter quarter were excluded.